IASO Bio achieves 95.9 percent response rate in FUCASO study
September 28, 2026 | 11:36
Biopharmaceutical firm IASO Bio presented clinical trial results showing a 95.9 percent objective response rate for its FUCASO therapy in patients with relapsed plasma cell neoplasms.
Mobile Version